低风险乳腺癌部分乳腺放疗:MRI引导自适应2期PARLOB研究
PARLOB研究纳入50例符合ESTRO指南的低风险乳腺癌患者,45例接受磁共振引导自适应立体定向部分乳腺放疗(5次6 Gy或6.5 Gy)。急性最高毒性为2级(20%),18个月时4例(9%)报告2级毒性,无≥3级毒性;患者和医生评估美容效果良好-优秀分别为90.9%和73.8%。
要点
- 低风险乳腺癌部分乳腺放疗采用MRI引导自适应立体定向技术可行,毒性低。
- 急性最高毒性为2级,发生率20%,主要为疲劳;无≥3级毒性。
- 18个月时患者自评美容效果(很)满意86.4%,良好-优秀90.9%。
核心结论
- 低风险乳腺癌患者采用立体定向磁共振引导自适应部分乳腺放疗可行,毒性发生率低。
- 随访18个月,患者报告的美容效果良好。
研究设计与样本
- 2期PARLOB研究,2017至2020年纳入50例符合ESTRO指南的低风险乳腺癌患者,45例接受SMART。
- SMART仰卧位,2周5次6 Gy,高危特征者6.5 Gy。
- 术后3、9、18、36个月评估患者和医生报告的毒性及美容效果。
主要发现
- 中位年龄66岁,中位肿瘤大小1.2 cm;Bloom Richardson 1级55.6%,雌激素受体阳性95.6%,80%未接受辅助全身治疗。
- 急性最高毒性为2级,发生率20%,主要为疲劳。
- 18个月时4例(9%)报告2级毒性,包括纤维化和疲劳;未记录到≥3级毒性。
- 9和18个月时86.4%患者对美容效果(很)满意。
- 18个月时与对侧乳腺相比,美容效果良好-优秀患者评分90.9%、医生评分73.8%。
关键数值与推荐
- 部分乳腺放疗适应证依据欧洲放射肿瘤学会(ESTRO)指南定义的低风险乳腺癌。
- SMART剂量方案:2周内5次6 Gy;高危特征者6.5 Gy。
临床怎么用
- 对符合ESTRO指南的低风险乳腺癌患者,可考虑采用SMART行部分乳腺放疗。
- 治疗期间及随访中关注疲劳、纤维化等2级毒性。
- 随访中同时采集患者和医生报告的美容效果。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The majority of patients with breast cancer are treated with breast-conserving surgery followed by postoperative whole or partial breast irradiation (PBI). Previous studies on PBI demonstrated similar ipsilateral breast tumor recurrences compared with whole breast irradiation, however, conflicting data on toxicity and cosmetic outcomes were reported. This study investigates the feasibility of stereotactic magnetic resonance imaging-guided adaptive radiation therapy (SMART) for PBI, with emphasis on toxicity and cosmetic outcomes. METHODS AND MATERIALS: Patients with low-risk breast cancer suitable for PBI as defined by European Society for Radiotherapy and Oncology guidelines were included. SMART was delivered in supine position in a 2-week course of 5 fractions of 6 Gy, or 6.5 Gy in case of high risk characteristics. Patient- and physician-reported toxicity and cosmetic outcomes were scored at 3, 9, 18, and 36 months postoperatively. RESULTS: Between 2017 and 2020, 50 patients were included and 45 patients were treated with SMART. Median age was 66 years, median tumor size was 1.2 cm. Most tumors were Bloom Richardson grade 1 (55.6%) and estrogen receptor positive (95.6%). The majority did not receive adjuvant systemic therapy (80%). The highest grade acute toxicity was grade 2 in 20%, mostly fatigue. At 18 months, 4 patients (9%) reported grade 2 toxicity, consisting of fibrosis and fatigue. No grade ≥3 toxicity was recorded. At 9 and 18 months, 86.4% of patients were (very) satisfied with the cosmetic outcome. The cosmetic outcome was good-excellent compared with the contralateral breast at 18 months in 90.9% and 73.8% as scored by patients and physicians, respectively. CONCLUSIONS: Stereotactic magnetic resonance imaging-guided adaptive PBI for patients with low-risk breast cancer was feasible and resulted in low rates of toxicity. Good cosmetic outcomes were reported by patients after a follow-up of 18 months.
引用
- van Vliet C, Tetar SU, van den Bongard HJGD, et al. Partial Breast Radiation Therapy in Low-Risk Breast Cancer Using a Magnetic Resonance Imaging-Guided Adaptive Approach; Results of the Phase 2 PARLOB Study. Pract Radiat Oncol. 2025. PMID: 40280483. doi:10.1016/j.prro.2025.03.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。